Entities / Company
CytomX Therapeutics (United States).
company in South San Francisco, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 31
What's happening
Gone quiet
No new reports in 90+ days-
Trump's pledge to unleash oil and gas benefits stocks, with CytomX Therapeutics analyzed through Benjamin Graham's investment philosophy.Some support1 report1 development inside
-
CytomX Therapeutics developed CX-2051 for colorectal cancer, while its leadership was updated, coinciding with market benefits from tariffs on AI stocks.Some support2 reports
-
CytomX Therapeutics developed therapeutic candidates, including Antibody-Drug Conjugates (ADCs).Some support2 reports1 development inside
-
CytomX Therapeutics announced clinical trial updates regarding its candidates, including CX-2051 for colorectal cancer and CX-801 for metastatic melanoma.Some support1 report
-
CytomX Therapeutics outperformed the S&P 500 market so far this year.Some support1 report
-
CytomX Therapeutics reported a patient death event to the FDA on August 15, 2025. Sean McCarthy serves as the CEO and chair.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around CytomX Therapeutics (United States) this week
News at the entities that move CytomX Therapeutics (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves CytomX Therapeutics (United States)
-
AbbVie OperationalAbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Moves CytomX Therapeutics (United States)
-
Moderna OperationalAnalyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Moves CytomX Therapeutics (United States)
-
Amgen OperationalAmgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Moves CytomX Therapeutics (United States)
Connections
The 4 strongest of 31, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Operational
AbbVie and CytomX Therapeutics are engaged in a formal partnership for collaborative drug discovery and revenue sharing.
-
FDA Structural
CytomX Therapeutics is subject to formal regulatory oversight by the FDA, requiring the reporting of adverse events.
-
Moderna Operational
Moderna and CytomX have established a strategic collaboration and partnership agreement for joint development of mRNA-encoded therapeutics.
-
Amgen Operational
CytomX and Amgen have established strategic collaborations focused on drug development.
History
Events by the month they beganJune 2026
6 events- Trump's pledge to unleash oil and gas benefits stocks, with CytomX Therapeutics analyzed through Benjamin Graham's investment philosophy.
- CytomX Therapeutics developed CX-2051 for colorectal cancer, while its leadership was updated, coinciding with market benefits from tariffs on AI stocks.
- CytomX Therapeutics developed therapeutic candidates, including Antibody-Drug Conjugates (ADCs).
- CytomX Therapeutics announced clinical trial updates regarding its candidates, including CX-2051 for colorectal cancer and CX-801 for metastatic melanoma.
- CytomX Therapeutics outperformed the S&P 500 market so far this year.
- CytomX Therapeutics reported a patient death event to the FDA on August 15, 2025. Sean McCarthy serves as the CEO and chair.